Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Sovereign Pharmaceuticals, LLC
EIR
•Sovereign Pharmaceuticals, LLC•November 10, 2016

Sovereign Pharmaceuticals, LLC – FDA EIR, Nov 10, 2016

Record Details

Sovereign Pharmaceuticals, LLC underwent an FDA inspection from November 7-10, 2016, at its Fort Worth, TX facility, focusing on human drug manufacturing. Conducted under FDA Compliance Programs for abbreviated drug process inspection and drug quality reporting, the review concluded with a four-item Form FDA 483, identifying significant issues related to Current Good Manufacturing Practice (CGMP).

Main violations included inadequate facility construction and cleaning, specifically dirty air ducts and vents in manufacturing areas, posing a contamination risk (21 CFR 211.42(a)). Employees failed to wear required mouth/nose covers during bulk blending operations, raising concerns about product protection (21 CFR 211.113(a)). The firm also lacked distinctive labeling for incoming Active Pharmaceutical Ingredients in the warehouse, impeding traceability and status identification (21 CFR 211.80(d)). Furthermore, the Quality Control Unit lacked written procedures for managing electronic data, including organizing HPLC project folders, defining user access levels, and establishing audit trail policies for the HPLC system (21 CFR 211.22(d)).

Management, led by the President and CEO, acknowledged the observations, committing to implement corrections and provide a written response within 15 business days. The FDA investigator underscored the potential for further regulatory action, such as product seizure or injunction, if non-compliance persists.

Company
Sovereign Pharmaceuticals, LLC
Inspection date
November 10, 2016
Product type
drugs
Office
Dallas District, Fort Worth Resident Post
People
  • Scott T. Ballard
  • Paul D. Hafey (recipient)
  • David E. Brown
  • Ralph Brown (company_representative)
  • Rob Chastain (company_representative)
View Company Profile

ID · 302fe4d2-a212-490f-8a6e-0fcd9f10f830

Violation Codes4
21 CFR 211.42(a)21 CFR 211.113(a)21 CFR 211.80(d)21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Sovereign Pharmaceuticals, LLC
  • 483 - 2025-05-12May 12, 2025
  • 483 - 2023-08-02August 2, 2023
  • WARNING_LETTER - 2022-04-22April 22, 2022
  • 483 - 2022-04-22April 22, 2022
  • 483 - 2021-09-01September 1, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sovereign Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.